Implementation of HER2DX Scores into Treatment Decisions in Early-Stage HER2-Positive Breast Cancer
Authors:
- Lola R. NogueiraLNLola R. Nogueira
- Ana MaderueloAMAna Maderuelo
- Manuel Alva BianchiMBManuel Alva Bianchi
- Pablo TolosaPTPablo Tolosa
- Laura LemaLLLaura Lema
- Juan MontesJMJuan Montes
- Teresa ZumárragaTZTeresa Zumárraga
- Ainhoa MadariagaAMAinhoa Madariaga
- Luis MansoLMLuis Manso
- Sofía Aragón SánchezSSSofía Aragón Sánchez
- Consuelo SanzCSConsuelo Sanz
- Yolanda RuanoYRYolanda Ruano
Open Access
- 11 June 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5293
Abstract
HER2DX is a 27-gene genomic assay generating three complementary scores: a pCR score predicting the likelihood of achieving pathological complete response (pCR, defined as absence of residual invasive disease after neoadjuvant therapy), a Risk score estimating long-term recurrence risk, and an ERBB2 mRNA score quantifying HER2 transcriptional activation. Together, these scores may guide treatment escalation or de-escalation strategies in routine practice. We performed a single-center observational study at 12 de Octubre University Hospital (Madrid, Spain), including patients with early-stage HER2-positive breast cancer who underwent HER2DX testing (2023–2025), and analyzed clinicopathologic features, treatment decisions, and pathological outcomes. Forty-five patients were included (median age 57 years). Stage II accounted for 71.1% of cases; 66.7% were hormone receptor-positive, and 31.3% were node-positive. HER2DX modified clinical management in 51.1% of patients. The pCR score changed the initial strategy (neoadjuvant therapy versus upfront surgery) in 17.8% of cases and, independently, favored de-escalation to taxane plus dual HER2 blockade, with 90% of high-score tumors achieving a pathological complete response. The Risk score informed chemotherapy backbone selection within stage II disease. The ERBB2 score correlated with HER2 immunohistochemical intensity. In this exploratory real-world cohort, HER2DX provided biologically distinct information beyond traditional immunohistochemistry and was associated with modifications in multidisciplinary treatment decision-making in early-stage HER2-positive breast cancer, warranting prospective validation in larger cohorts.Keywords
This publication has 24 references indexed in Scilit:
- 149TiP DEFINITIVE TRIAL: Diagnostic HER2DX-guided treatment for patIents wIth early-stage HER2-positive breast cancerESMO Open, 2025
- Clinical decision impact of HER2DX, an algorithm-powered genomic diagnostic in early-stage HER2-positive breast cancer: results from a prospective real-world studyESMO Real World Data and Digital Oncology, 2025
- Linking tumor immune infiltration to enhanced longevity in recurrence-free breast cancerESMO Open, 2025
- Heterogeneity of Residual Disease After Neoadjuvant Systemic Therapy in Breast CancerJAMA Oncology, 2024
- Analytical validation of HER2DX genomic test for early-stage HER2-positive breast cancerESMO Open, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancerAnnals of Oncology, 2023
- Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerEBioMedicine, 2022
- Dissecting the biological heterogeneity of HER2-positive breast cancerThe Breast, 2021
- HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysisCancer Treatment Reviews, 2020